Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 182.95M | $ 17.45M | $ 25.82M | $ 57.03M | $ 0.00 |
| Gross Profit | $ 170.13M | $ 15.85M | $ 24.86M | $ 54.95M | $ -246.00K |
| Operating Income | $ -120.57M | $ -143.16M | $ -62.71M | $ -12.16M | $ -26.98M |
| EBITDA | $ -106.48M | $ -131.67M | $ -59.70M | $ -13.46M | $ -26.56M |
| Net Income | $ -115.55M | $ -135.89M | $ -62.09M | $ -13.83M | $ -26.81M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 291.38M | $ 227.44M | $ 217.03M | $ 171.81M | $ 168.13M |
| Total Assets | $ 376.99M | $ 265.49M | $ 227.86M | $ 178.91M | $ 171.97M |
| Total Debt | $ 72.45M | $ 30.22M | $ 20.21M | $ 1.89M | $ 831.00K |
| Net Debt | $ -22.37M | $ -194.73M | $ -51.45M | $ -169.44M | $ -167.30M |
| Total Liabilities | $ 152.46M | $ 68.50M | $ 34.96M | $ 12.18M | $ 5.99M |
| Stockholders' Equity | $ 224.53M | $ 196.99M | $ 192.90M | $ 166.73M | $ 165.98M |
| Cash Flow | |||||
| Free Cash Flow | $ -84.59M | $ -123.00M | $ -49.54M | $ 3.16M | $ -21.59M |
| Operating Cash Flow | $ -83.03M | $ -117.49M | $ -49.03M | $ 3.75M | $ -21.14M |
| Investing Cash Flow | $ -199.19M | $ 140.60M | $ -144.63M | $ -586.00K | $ -456.00K |
| Financing Cash Flow | $ 154.66M | $ 130.18M | $ 93.99M | $ 21.00K | $ 131.77M |